Do Phase III Trials Have Clinical Value?
- 1 October 1999
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 19 (5) , 391-392
- https://doi.org/10.1097/00004714-199910000-00001
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Comments on Article by Tran and Colleagues, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders"Journal of Clinical Psychopharmacology, 1998
- Olanzapine on TrialAmerican Journal of Psychiatry, 1998
- Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placeboBiological Psychiatry, 1997
- Extrapyramidal Signs and Clinical Symptoms in First-Episode SchizophreniaJournal of Clinical Psychopharmacology, 1997
- Quetiapine in Patients With SchizophreniaArchives of General Psychiatry, 1997
- Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trialAmerican Journal of Psychiatry, 1997
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus HaloperidolThe British Journal of Psychiatry, 1995
- Risperidone in the treatment of schizophreniaAmerican Journal of Psychiatry, 1994
- Clozapine for the Treatment-Resistant SchizophrenicArchives of General Psychiatry, 1988